LYRM1抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Mouse adipose tissue lysates, Primary antibody: P09985(LYRM1 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09985(LYRM1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09985(LYRM1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The LYRM1 (LYR Motif Containing 1) antibody is a tool used to study the LYRM1 protein, a member of the LYR family characterized by conserved leucine-tyrosine-arginine (LYR) motifs. LYRM1 is primarily localized to mitochondria and is implicated in the assembly or stabilization of iron-sulfur (Fe-S) clusters, essential cofactors for enzymes involved in oxidative phosphorylation, DNA repair, and metabolic pathways. It interacts with components of the mitochondrial electron transport chain, particularly Complex III (ubiquinol-cytochrome c reductase), suggesting a role in maintaining mitochondrial function and energy metabolism.

Research on LYRM1 has gained traction due to its potential links to mitochondrial disorders, neurodegenerative diseases, and metabolic syndromes. Antibodies targeting LYRM1 enable the detection, quantification, and subcellular localization of the protein in various experimental models, including immunoblotting, immunofluorescence, and immunohistochemistry. These studies help elucidate LYRM1's molecular interactions, its role in Fe-S cluster biogenesis, and its impact on cellular redox balance. Commercial LYRM1 antibodies are typically validated in human, mouse, or rat tissues, with applications spanning basic research and translational studies exploring mitochondrial dysfunction. Recent investigations also explore its expression patterns in cancer, where altered mitochondrial metabolism is a hallmark, positioning LYRM1 as a potential biomarker or therapeutic target.